• News
  • Stock Screener
  • Small Caps
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Review
  • X (Twitter)

Stock Screener

Show:

Sort

Country

Sector

Risk rating

1
2
3
4
5
6
7

Risk factors

    Default risk

    1
    2
    3
    4
    5
    6
    7

    Volatility

    1
    2
    3
    4
    5
    6
    7

    Stress test

    1
    2
    3
    4
    5
    6
    7

    Selling difficulty

    1
    2
    3
    4
    5
    6
    7

    Country risks

    1
    2
    3
    4
    5
    6
    7

    Other risks

    1
    2
    3
    4
    5
    6
    7

Profitability factors

    Valuation

    1
    2
    3
    4
    5
    6
    7

    Analyst view

    1
    2
    3
    4
    5
    6
    7

    Performance

    1
    2
    3
    4
    5
    6
    7

    Profitability

    1
    2
    3
    4
    5
    6
    7

    Growth

    1
    2
    3
    4
    5
    6
    7

    Dividends

    1
    2
    3
    4
    5
    6
    7

    Results: 65

    SINO BIOPHARM

    1177.HK
    5

    ALI HEALTH

    0241.HK
    2

    The United Laboratories International Holdings Limited

    3933.HK
    5

    HUTCHMED

    0013.HK
    4

    GRAND PHARMA

    0512.HK
    5

    SIHUAN PHARM

    0460.HK
    3

    CMS

    0867.HK
    4

    Guangdong Hybribio Biotech Co.,Ltd.

    300639.SZ
    2

    China Resources Pharmaceutical Group Limited

    3320.HK
    6

    TRAD CHI MED

    0570.HK
    3

    SinoMab BioScience Limited

    3681.HK
    1

    SSY Group Limited

    2005.HK
    5

    Regencell Bioscience Holdings Limited

    RGC
    2

    Beijing Tong Ren Tang Chinese Medicine Company Limited

    3613.HK
    5

    Prenetics Global Limited

    PRE
    3

    Sirnaomics Ltd.

    2257.HK
    2

    LEE'S PHARM

    0950.HK
    5

    CKLIFE SCIENCES

    0775.HK
    2

    Chia Tai Enterprises International Limited

    3839.HK
    3

    UNI-BIO GROUP

    0690.HK
    3
X-channel

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • X (Twitter)
Oninvest© 2025